None listed
Conditions
Interventions
Dietary Supplement : • Lactiplantibacillus plantarum HY7714 group: two capsules per day, orally after breakfast for 12 weeks (daily dose: 1 g/Lactiplantibacillus plantarum HY7714 dose: 1×10^10 CFU/da
Sponsors
Hy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult males and females aged 30 to 60 at the time of the screening test. 2. Individuals who fall under Fitzpatrick skin type categories 1 to 4. 3. Individuals with a skin moisture level of 49 A.U. or less, and a crow's feet wrinkle grade of Grade 3 or higher. 4. Individuals who have received a detailed explanation of this human application test, fully understood it, voluntarily decided to participate, and have given written consent to comply with the precautions.
Exclusion criteria
Exclusion criteria: 1. Individuals with skin diseases such as sensitivity, hypersensitivity, eczema, or psoriasis. 2. Individuals with abnormal skin findings on the test area, such as moles, acne, erythema, telangiectasia, burn marks, scars, or tattoos. 3. Individuals who have used topical steroid preparations or taken oral retinoids/steroids within 3 months prior to the screening test. 4. Individuals who have used functional cosmetics for wrinkle improvement, high-moisturizing cosmetics, or skin care devices within 2 weeks prior to the screening test. 5. Individuals who have undergone facial procedures within 1 month prior to the screening test, or have received facial procedures such as Botox or fillers within 6 months. 6. Individuals who have taken obesity treatments, contraceptives, hormones, or diuretics within 1 month prior to the screening test. 7. Individuals who are continuously exposed to or plan to be exposed to excessive sunlight or ultraviolet light. 8. Individuals with a history of photoallergy or photosensitization. 9. Individuals who have been taking functional health foods or quasi-drugs for the purpose of skin hydration or wrinkle improvement within 1 month prior to the screening test. 10. Individuals allergic to cosmetics, pharmaceuticals, or quasi-drugs. 11. Individuals with uncontrolled hypertension or diabetes. 12. Individuals with excessive alcohol consumption. 13. Individuals with excessive smoking. 14. Individuals with experience receiving antipsychotic drug treatment within 3 months prior to the screening test. 15. Individuals who have or are suspected of having alcoholism or drug abuse. 16. Individuals with a history of significant hypersensitivity reactions to raw ingredients. 17. Individuals who have participated in another human application test within 3 months prior to the screening test. 18. Individuals who are pregnant, breastfeeding, planning to become pregnant within 6 months, or do not agree to contraception during the test period. 19. Individuals deemed unsuitable for research participation by the principal investigator due to diagnostic laboratory test results or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin wrinkle-related indicators;skin moisture-related indicators;pigmentation-related indicators;skin health-related blood indicators; PGA(Patient Global Assessment)) | — |
Countries
Korea, Republic of
Contacts
Public ContactJu hee Lee
Yonsei University Health System, Severance Hospital
Outcome results
None listed